Clinical Trials

Study Title:
Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

For more information about the trial above please contact the study team:

Principal Investigator, Mariam Alexander, at alexanma@musc.edu.

Study Coordinator, Alexandra Leitner, at leitnera@musc.edu, or please call +1 843-792-1507.

Trial opened at the following institutions: Medical University of South Carolina